Aurobindo Pharma gets DCGI's permission to manufacture, distribute generic version of Molnupiravir
Source: IRIS | 30 Dec, 2021, 10.55AM
|
|
|
|
|
| Rating: NAN / 5 stars. |
 Comments | Post Comment |
|
 Aurobindo Pharma, a mid-size pharmaceutical company, has received the Drugs Controller General of India’s (DCGI’s) permission to manufacture and distribute its in-licensed generic version of MSD (a trade name of Merck & Co., Inc, Kenilworth, NJ, USA) and Ridgeback’s Molnupiravir, to be marketed as Molnaflu.
Earlier this year, Aurobindo had signed a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme, Singapore (MSD), a subsidiary of Merck & Co. (US) to manufacture and supply Molnupiravir to over 100 low and middle-income countries (LMIC), including India.
Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (UKMHRA) for the treatment of mild-to-moderate COVID -19 in adults. It has also been recently approved by the U.S. Food and Drug Administration (USFDA) and under Emergency Use Authorisation (EUA).
K. Nithyananda Reddy, Vice Chairman, Aurobindo said, "We are delighted with the timely permission from DCGI forthe generic version of Molnupiravir as it opens up access to an affordable treatment option for COVID19 patients and enable us to help battle the pandemic with effective and high-quality pharmaceutical products. We are glad to have partnered with MSD on this product and are committed to enhance access to this product for patients in need, in our partnered territories. The product progresses our mission of being committed to healthier life."
Shares of the company gained Rs 1.10 or 0.15%, to trade at Rs 727.75. The total volume of shares traded was 4,759 at the BSE (9.24 a.m, Thursday).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
